Expert NetworkExpert InterviewGILD

Slingshot members are talking to an expert! The topic is:

Investigating the recent FDA approval for Yeztugo® (lenacapavir) as a pre-exposure prophylaxis for sexually acquired HIV by Gilead Sciences

Executed on:Sep 17, 2025 5:30 PM EDT
Call Duration:30 minutes

Expert Profile

ExpertBlinded Expert
Institution: Boston University
  • Associate Professor of Medicine and Microbiology
  • treats about 20 patients per year for urogenital gonorrhea and is familiar the Phase 2 study of Gepotidacin for the treatment of uncomplicated urogenital gonorrhea
  • Research interetst in human immunodeficiency virus type 1 (HIV-1) mucosal HIV-1 transmission and antibodies with a focus on the biological mechanisms for the selection observed during HIV-1 transmission

Interview Goal

To gain insight on the impact of Gileade Science, Inc.'s Yeztugo, the first and FDA-approved HIV prevention option that offers 6 months of protection.

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.